← Leaderboards
Khashayar Sakhaee
University Of Texas Sw Med Ctr/Dallas
$14,492,169
Attributed
$18,736,590
Total exposure
36
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $960K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$18,736,590 · 36
By mechanism
M01$9,303,162 · 32
R01$8,302,859 · 2
P01$1,130,569 · 2
Top collaborators
- Orson W Moe15 shared
- Jeffrey D Browning5 shared
- Naim M Maalouf5 shared
- Ming-Chang Hu4 shared
Most similar at University Of Texas Sw Med Ctr/Dallas
Same institution · by research overlap
- Charles Y.c Pak$11,557,463
- Naim M Maalouf$8,442,081
- Margaret S. Pearle$3,288,901
- Howard J Heller$2,980,605
- Craig D Rubin$2,077,007
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectNephrolithiasisOsteoporosisUrineUrinaryPrecipitationExcretory FunctionCalciumKidney CalculiUric AcidKidneyDefectAnimalsFundingMetabolic SyndromeBaseAcidsCitratesFatty Acid Glycerol EstersPathogenesisUrateObesitySource
Grant awards (90)
Pathogenesis of Uric Acid Nephrolithiasis$502,962
R01 · FY2023 · DK · contact PI
Origin of Excess Acid in Uric Acid Urolithiasis$449,722
R01 · FY2023 · DK
Pathogenesis of Uric Acid Nephrolithiasis$510,253
R01 · FY2022 · DK · contact PI
Origin of Excess Acid in Uric Acid Urolithiasis$449,722
R01 · FY2022 · DK
Pathogenesis of Uric Acid Nephrolithiasis$508,607
R01 · FY2021 · DK · contact PI
Origin of Excess Acid in Uric Acid Urolithiasis$449,495
R01 · FY2021 · DK
Pathogenesis of Uric Acid Nephrolithiasis$505,438
R01 · FY2020 · DK · contact PI
Origin of Excess Acid in Uric Acid Urolithiasis$448,124
R01 · FY2020 · DK
Pathogenesis of Uric Acid Nephrolithiasis$500,648
R01 · FY2019 · DK · contact PI
Origin of Excess Acid in Uric Acid Urolithiasis$446,980
R01 · FY2019 · DK
Pathogenesis of Uric Acid Nephrolithiasis: The Multifaceted Role of Renal Lipids$357,750
R01 · FY2018 · DK · contact PI
Pathogenesis of Uric Acid Nephrolithiasis: The Multifaceted Role of Renal Lipids$357,750
R01 · FY2017 · DK · contact PI
Pathogenesis of Uric Acid Nephrolithiasis: The Multifaceted Role of Renal Lipids$357,750
R01 · FY2016 · DK · contact PI
Pathogenesis of Uric Acid Nephrolithiasis: The Multifaceted Role of Renal Lipids$357,750
R01 · FY2015 · DK · contact PI
Pathogenesis of Uric Acid Nephrolithiasis: The Multifaceted Role of Renal Lipids$357,750
R01 · FY2014 · DK · contact PI
Pathogenesis of Idiopathic Uric Acid Nephrolithiasis: The Role of Renal Lipotoxic$322,966
R01 · FY2013 · DK · contact PI
Pathogenesis of Idiopathic Uric Acid Nephrolithiasis and Renal Lipotoxicity$334,680
R01 · FY2012 · DK · contact PI
Pathogenesis of Idiopathic Uric Acid Nephrolithiasis: The Role of Renal Lipotoxic$334,680
R01 · FY2011 · DK · contact PI
Pathogenesis of Idiopathic Uric Acid Nephrolithiasis: The Role of Renal Lipotoxic$373,032
R01 · FY2010 · DK · contact PI
Pathogenesis of Idiopathic Uric Acid Nephrolithiasis: The Role of Renal Lipotoxic$376,800
R01 · FY2009 · DK · contact PI
PATHOPHYSIOLOGY OF IDIOPATHIC URIC ACID NEPHROLITHIASIS$182,924
P01 · FY2008 · DK · contact PI
PATHOPHYSIOLOGY OF IDIOPATHIC URIC ACID NEPHROLITHIASIS$189,657
P01 · FY2007 · DK · contact PI
INTEGRATED ASSESSMENT OF CALCIUM METABOLISM$42,335
M01 · FY2007 · RR · contact PI
PATHOPHYSIOLOGY AND MOLECULAR GENETIC BASIS OF GOUTY DIATHESIS$21,322
M01 · FY2007 · RR · contact PI
EFFECT OF POTASSIUM ALKALI ON BONE LOSS AND STONE RISK INDUCED BY ATKINS' DIET$13,257
M01 · FY2007 · RR · contact PI
DIURNAL VARIATION OF URINARY PH$5,702
M01 · FY2007 · RR · contact PI
COMBINED SODIUM FLUORIDE AMP; CALCIUM CITRATE THERAPY IN OSTEOPOROSIS$2,929
M01 · FY2007 · RR · contact PI
K CITRATE AND STONE RISK IN PATIENTS ON TOPIRAMATE$1,286
M01 · FY2007 · RR · contact PI
POST-TRANSPLANT PHOSPHATURIA: DURATION AND PATHOGENESIS$823
M01 · FY2007 · RR · contact PI
MEDICAL EVALUATION AND TREATMENT OF OSTEOPOROSIS$619
M01 · FY2007 · RR · contact PI
ALTERNATIVE ASSESSMENT OF INTESTINAL CALCIUM ABSORPTION$566
M01 · FY2007 · RR · contact PI
PATHOPHYSIOLOGY AND MOLECULAR GENETIC BASIS OF GOUTY DIATHESIS$232,027
M01 · FY2006 · RR · contact PI
INTEGRATED ASSESSMENT OF CALCIUM METABOLISM$185,681
M01 · FY2006 · RR · contact PI
PATHOPHYSIOLOGY OF IDIOPATHIC URIC ACID NEPHROLITHIASIS$181,723
P01 · FY2006 · DK · contact PI
EFFECT OF POTASSIUM ALKALI ON BONE LOSS AND STONE RISK INDUCED BY ATKINS' DIET$117,194
M01 · FY2006 · RR · contact PI
DIURNAL VARIATION OF URINARY PH$112,471
M01 · FY2006 · RR · contact PI
COMBINED SODIUM FLUORIDE & CALCIUM CITRATE THERAPY IN OSTEOPOROSIS$16,531
M01 · FY2006 · RR · contact PI
ALTERNATIVE ASSESSMENT OF INTESTINAL CALCIUM ABSORPTION$1,771
M01 · FY2006 · RR · contact PI
PATHOPHYSIOLOGY AND MOLECULAR GENETIC BASIS OF GOUTY DIATHESIS$299,385
M01 · FY2005 · RR
INTEGRATED ASSESSMENT OF CALCIUM METABOLISM$225,423
M01 · FY2005 · RR
PATHOPHYSIOLOGY OF IDIOPATHIC URIC ACID NEPHROLITHIASIS$176,428
P01 · FY2005 · DK
DIURNAL VARIATION OF URINARY PH$56,976
M01 · FY2005 · RR
STONE RISK OF ESTROGEN IN EARLY AND LATE MENOPAUSE$24,064
M01 · FY2005 · RR
COMBINED SODIUM FLUORIDE &CALCIUM CITRATE THERAPY IN OSTEOPOROSIS$21,941
M01 · FY2005 · RR
EFFECT OF POTASSIUM ALKALI ON BONE LOSS AND STONE RISK INDUCED BY ATKINS'DIET$20,171
M01 · FY2005 · RR
Pathophysiology and Molecular Genetic Basis of Gouty Diathesis$258,467
M01 · FY2004 · RR
Combined treatment in the prevention of postmenopausal bone loss$252,487
M01 · FY2004 · RR
Integrated Assessment of Calcium Metabolism$217,715
M01 · FY2004 · RR
PATHOPHYSIOLOGY OF IDIOPATHIC URIC ACID NEPHROLITHIASIS$171,290
P01 · FY2004 · DK
Combined Sodium Fluoride &Calcium Citrate Therapy in Osteoporosis$23,034
M01 · FY2004 · RR
Effects of Smoking and Smoking Cessation on Bone Mineral Metabolism$5,316
M01 · FY2004 · RR
Assessment of Toxic Skeletal Fluoride Threshold$3,101
M01 · FY2004 · RR
Stone Risk of Estrogen in Early and Late Menopause$443
M01 · FY2004 · RR
Hydrochlorothiazide and 1,25-(OH)(2) Vitamin D in Osteoporosis$221
M01 · FY2004 · RR
FLUORIDE BIOAVAILABLITY--EFFECT OF STANDARD BREAKFAST AND CITRACAL$321,374
M01 · FY2002 · RR
BONE SPARING ACTION OF K MAG CITRATE: COMPARISON W/ CALCIUM CITRATE$321,374
M01 · FY2002 · RR
PATHOPHYSIOLOGY AND MOLECULAR GENETIC BASIS OF GOUTY DIATHESIS$321,374
M01 · FY2002 · RR
PHARMACOKINETICS OF BIOEQUIVALENT DOSES OF FLUORIDES$321,374
M01 · FY2002 · RR
PHYSIOLOGICAL AND GENETIC ELUCIDATION OF GOUTY DIATHESIS$321,374
M01 · FY2002 · RR
EFFECT OF ENALAPRIL ON URINARY CITRATE EXCRETION$321,374
M01 · FY2002 · RR
ASSESSMENT OF TOXIC SKELETAL FLUORIDE THRESHOLD$321,374
M01 · FY2002 · RR
UROPHOS-K FOR THE TREATMENT OF IDIOPATHIC OSTEOPOROSIS$321,374
M01 · FY2002 · RR
COMBINED SODIUM FLUORIDE AND CALCIUM CITRATE THERAPY IN OSTEOPOROSIS$321,374
M01 · FY2002 · RR
CALCIUM CITRATE AND PROPENSITY FOR CRYSTALLIZATION OF CALCIUM SALTS$321,374
M01 · FY2002 · RR
HYDROCHLOROTHIAZIDE AND 1,25-(OH)(2) VITAMIN D IN OSTEOPOROSIS$321,374
M01 · FY2002 · RR
GOUTY DIATHESIS--PATHOPHYSIOLOGY AND MOLECULAR GENETIC BASIS$228,547
P01 · FY2002 · DK
BONE SPARING ACTION OF K MAG CITRATE: COMPARISON W/ CALCIUM CITRATE$321,374
M01 · FY2001 · RR
PATHOPHYSIOLOGY AND MOLECULAR GENETIC BASIS OF GOUTY DIATHESIS$321,374
M01 · FY2001 · RR
PHARMACOKINETICS OF BIOEQUIVALENT DOSES OF FLUORIDES$321,374
M01 · FY2001 · RR
FLUORIDE BIOAVAILABLITY--EFFECT OF STANDARD BREAKFAST AND CITRACAL$321,374
M01 · FY2001 · RR
PHYSIOLOGICAL AND GENETIC ELUCIDATION OF GOUTY DIATHESIS$321,374
M01 · FY2001 · RR
COMBINED SODIUM FLUORIDE AND CALCIUM CITRATE THERAPY IN OSTEOPOROSIS$321,374
M01 · FY2001 · RR
CALCIUM CITRATE AND PROPENSITY FOR CRYSTALLIZATION OF CALCIUM SALTS$321,374
M01 · FY2001 · RR
HYDROCHLOROTHIAZIDE AND 1,25-(OH)(2) VITAMIN D IN OSTEOPOROSIS$321,374
M01 · FY2001 · RR
EFFECT OF ENALAPRIL ON URINARY CITRATE EXCRETION$321,374
M01 · FY2001 · RR
ASSESSMENT OF TOXIC SKELETAL FLUORIDE THRESHOLD$321,374
M01 · FY2001 · RR
UROPHOS-K FOR THE TREATMENT OF IDIOPATHIC OSTEOPOROSIS$321,374
M01 · FY2001 · RR
GOUTY DIATHESIS--PATHOPHYSIOLOGY AND MOLECULAR GENETIC BASIS$0
P01 · FY2001 · DK
EFFECT OF ENALAPRIL ON URINARY CITRATE EXCRETION$34,838
M01 · FY2000 · RR
CALCIUM CITRATE AND PROPENSITY FOR CRYSTALLIZATION OF CALCIUM SALTS$34,838
M01 · FY2000 · RR
COMBINED SODIUM FLUORIDE AND CALCIUM CITRATE THERAPY IN OSTEOPOROSIS$0
M01 · FY2000 · RR
GOUTY DIATHESIS--PATHOPHYSIOLOGY AND MOLECULAR GENETIC BASIS$0
P01 · FY2000 · DK
BONE SPARING ACTION OF K MAG CITRATE--COMPARISON W/ CALCIUM CITRATE$0
M01 · FY2000 · RR
PATHOPHYSIOLOGY &MOLECULAR GENETIC BASIS OF GOUTY DIATHESIS$0
M01 · FY2000 · RR
PHARMACOKINETICS OF BIOEQUIVALENT DOSES OF FLUORIDES$0
M01 · FY2000 · RR
HYDROCHLOROTHIAZIDE AND 1,25-(OH)(2) VITAMIN D IN OSTEOPOROSIS$0
M01 · FY2000 · RR
PHYSIOLOGICAL AND GENETIC ELUCIDATION OF GOUTY DIATHESIS$0
M01 · FY2000 · RR
ASSESSMENT OF TOXIC SKELETAL FLUORIDE THRESHOLD$0
M01 · FY2000 · RR
UROPHOS-K FOR THE TREATMENT OF IDIOPATHIC OSTEOPOROSIS$0
M01 · FY2000 · RR
ASSESSMENT OF CALCIUM METABOLISM IN DISORDER OF MINERAL METABOLISM$0
M01 · FY2000 · RR